LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer

Abstract excerpt

Although the presence of nuclear estrogen receptor is widely used to guide breast cancer therapy, less attention has been paid to the receptor cytoplasmic signaling. Recently, we have shown that this pathway is operative in vivo and is activated in aggressive tumors representing a new potential target for breast cancer therapy. Here, we identified LKB1 as a partner of ERα and we explored its potential role in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related Molecular Pathways
• Share to Genetic factors in colorectal cancer
• Share to Metabolism, Diabetes, and Cancer